Literature DB >> 27811860

Evaluation of a Web-based decision aid for people considering the APOE genetic test for Alzheimer risk.

Michael Ekstract1, Golde I Holtzman2, Kye Y Kim3, Susan M Willis4, Doris T Zallen5,6.   

Abstract

PURPOSE: With the increasing interest in apolipoprotein E (APOE) genetic testing to estimate the risk of developing late-onset Alzheimer disease, new educational tools are needed to help people make the best decision for themselves about whether to undergo this test. This study evaluated an online tool to assist in this decision process.
METHODS: A prototype decision aid was studied in a two-part survey that collected data from participants before and after they examined the decision aid. Both surveys had multiple-choice options and opportunities for open-ended responses, yielding quantitative and qualitative information. The responses before and after use of the aid were compared for each participant.
RESULTS: A total of 1,262 individuals completed both surveys. The overall effectiveness of the decision aid was shown by three measures: 94% found the decision aid very helpful or somewhat helpful; general knowledge was increased; and some people changed their minds about APOE genetic testing, with 35% shifting to a higher likelihood of undergoing the test and 20% to a lower likelihood. Suggestions for improvements were noted and incorporated into the online tool.
CONCLUSION: This decision aid can provide useful educational assistance to many individuals as they consider APOE genetic testing as well as facilitate further discussions with their health-care providers.Genet Med advance online publication 03 November 2016.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27811860     DOI: 10.1038/gim.2016.170

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  17 in total

1.  APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: the Cache County Study.

Authors:  J C Breitner; B W Wyse; J C Anthony; K A Welsh-Bohmer; D C Steffens; M C Norton; J T Tschanz; B L Plassman; M R Meyer; I Skoog; A Khachaturian
Journal:  Neurology       Date:  1999-07-22       Impact factor: 9.910

2.  Developing a quality criteria framework for patient decision aids: online international Delphi consensus process.

Authors:  Glyn Elwyn; Annette O'Connor; Dawn Stacey; Robert Volk; Adrian Edwards; Angela Coulter; Richard Thomson; Alexandra Barratt; Michael Barry; Steven Bernstein; Phyllis Butow; Aileen Clarke; Vikki Entwistle; Deb Feldman-Stewart; Margaret Holmes-Rovner; Hilary Llewellyn-Thomas; Nora Moumjid; Al Mulley; Cornelia Ruland; Karen Sepucha; Alan Sykes; Tim Whelan
Journal:  BMJ       Date:  2006-08-14

Review 3.  Using Alzheimer's disease as a model for genetic risk disclosure: implications for personal genomics.

Authors:  J S Roberts; K D Christensen; R C Green
Journal:  Clin Genet       Date:  2011-07-18       Impact factor: 4.438

Review 4.  Interventions to improve patient education regarding multifactorial genetic conditions: a systematic review.

Authors:  Katherine G Meilleur; Marguerite T Littleton-Kearney
Journal:  Am J Med Genet A       Date:  2009-02-15       Impact factor: 2.802

5.  Disclosure of APOE genotype for risk of Alzheimer's disease.

Authors:  Robert C Green; J Scott Roberts; L Adrienne Cupples; Norman R Relkin; Peter J Whitehouse; Tamsen Brown; Susan LaRusse Eckert; Melissa Butson; A Dessa Sadovnick; Kimberly A Quaid; Clara Chen; Robert Cook-Deegan; Lindsay A Farrer
Journal:  N Engl J Med       Date:  2009-07-16       Impact factor: 91.245

6.  Reluctance to undergo predictive testing: the case of Huntington disease.

Authors:  K A Quaid; M Morris
Journal:  Am J Med Genet       Date:  1993-01-01

Review 7.  Apolipoprotein E genotyping in Alzheimer's disease. National Institute on Aging/Alzheimer's Association Working Group.

Authors: 
Journal:  Lancet       Date:  1996-04-20       Impact factor: 79.321

8.  Effectiveness of a condensed protocol for disclosing APOE genotype and providing risk education for Alzheimer disease.

Authors:  J Scott Roberts; Clara A Chen; Wendy R Uhlmann; Robert C Green
Journal:  Genet Med       Date:  2012-04-12       Impact factor: 8.822

9.  Direct-to-consumer genetic testing: a revised position statement of the American College of Medical Genetics and Genomics.

Authors: 
Journal:  Genet Med       Date:  2015-12-17       Impact factor: 8.822

10.  Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors.

Authors:  Jill S Goldman; Susan E Hahn; Jennifer Williamson Catania; Susan LaRusse-Eckert; Melissa Barber Butson; Malia Rumbaugh; Michelle N Strecker; J Scott Roberts; Wylie Burke; Richard Mayeux; Thomas Bird
Journal:  Genet Med       Date:  2011-06       Impact factor: 8.822

View more
  3 in total

1.  Clinical implications of APOE genotyping for late-onset Alzheimer's disease (LOAD) risk estimation: a review of the literature.

Authors:  Victoria S Marshe; Ilona Gorbovskaya; Sarah Kanji; Maxine Kish; Daniel J Müller
Journal:  J Neural Transm (Vienna)       Date:  2018-10-31       Impact factor: 3.575

Review 2.  Genetic testing for neurodegenerative diseases: Ethical and health communication challenges.

Authors:  J Scott Roberts; Anne K Patterson; Wendy R Uhlmann
Journal:  Neurobiol Dis       Date:  2020-04-14       Impact factor: 5.996

Review 3.  Informed Consent in the Genomics Era.

Authors:  Shannon Rego; Megan E Grove; Mildred K Cho; Kelly E Ormond
Journal:  Cold Spring Harb Perspect Med       Date:  2020-08-03       Impact factor: 5.159

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.